# Vir Biotechnology Vir Biotechnology is an Asset Manager based in San Francisco, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** San Francisco, United States - **Region:** North America - **Address:** San Francisco, CA, United States - **Founded:** 2016 - **Assets under management:** Undisclosed - **Website:** vir.bio - **LinkedIn:** https://www.linkedin.com/company/vir-biotechnology-inc ## Regulatory record - **Reports private funds:** No ## About Vir Biotechnology was founded in 2016 by former Biogen CEO George Scangos, ARCH Venture Partners co-founder Robert Nelsen, and a group of scientists who believed monoclonal antibody engineering could be applied systematically to infectious disease. The firm launched with a $150 million Series A and an unusual asset-acquisition model — licensing platform technology from academic labs and biotechs, then developing it through clinical trials internally. It was designed to function like a portfolio company of a venture capital firm rather than a traditional drug discovery startup, with ARCH and later investors including SoftBank, Temasek, and the Bill & Melinda Gates Foundation backing its target-agnostic platform. The company's strategy centers on internalizing external innovation and applying deep immunological expertise to shepherd assets from preclinical concept through regulatory approval. It deploys capital across antibody therapeutics, T-cell engagers, and prophylactic vaccines, using a proprietary machine-learning platform to identify broadly neutralizing antibodies against viruses including influenza, hepatitis B, HIV, and SARS-CoV-2. Its most recognized asset, the monoclonal antibody sotrovimab, was developed in partnership with GSK and authorized for emergency use by the FDA in May 2021, generating over $2 billion in sales that year (per GSK earnings, 2022). The firm also holds a significant pipeline position in chronic hepatitis B through a collaboration with Alnylam Pharmaceuticals and maintains research operations in San Francisco, Portland, and Bellinzona, Switzerland. Vir operated with roughly 600 employees at peak COVID development and subsequently restructured to focus on its most capital-efficient programs. In April 2024, the company announced a corporate restructuring that reduced the workforce by approximately 12% and narrowed its pipeline to prioritize chronic hepatitis B, influenza, and its T-cell engager platform in oncology (per the firm, April 2024). CEO Marianne De Backer, who succeeded Scangos in early 2023, brought a partnership-driven strategy honed at Bayer and Johnson & Johnson, expanding Vir's reach into solid tumors while maintaining the infectious disease core. The firm's clinical portfolio now spans Phase 2 trials in hepatitis B, Phase 1 trials in influenza A, and preclinical programs exploring both infectious disease and oncology applications. Vir's structural distinction comes from operating a dual-mandate R&D model that functions like a disclosure-optimized asset manager — raising public capital to build and trade a portfolio of drug programs rather than anchoring to a single modality or disease area. Unlike traditional biotechs that rise and fall on one lead candidate, Vir maintains clinical programs across viral hepatitis, respiratory viruses, and oncology simultaneously, with the explicit ability to wind down programs, return capital, or spin assets into new entities depending on clinical data and partnership economics. This portfolio-company architecture — born from venture capital logic rather than pharmaceutical R&D tradition — gives institutional allocators a liquid, publicly traded vehicle that behaves more like a fund than a drug company. ## Sectors - Infectious Disease - Immunology - AI/ML ## Offices - Bellinzona, Switzerland - Portland, OR, United States ## People - George Scangos — Co-Founder and Former CEO - Marianne De Backer — Chief Executive Officer - Robert Nelsen — Co-Founder and Chairman ## Questions ### Who runs investment and pipeline decisions at Vir Biotechnology? CEO Marianne De Backer leads strategic R&D allocation and capital deployment, succeeding co-founder George Scangos in early 2023. De Backer previously ran mergers and acquisitions and business development at Bayer and held executive roles at Johnson & Johnson, bringing a deal-oriented approach to pipeline management. The board includes ARCH Venture Partners' Robert Nelsen, whose firm incubated the company, and representation from major institutional shareholders. Pipeline priorities are set by a clinical advisory process that gates programs based on external data readouts and partnership economics rather than traditional pharma blockbuster forecasting. ### How does Vir Biotechnology source its assets and intellectual property? Vir acquires platform technologies and clinical-stage assets through academic licensing agreements and biotech partnerships rather than relying on internal discovery. It holds licenses from the University of Texas, University of Washington, and the University of Zurich, among others, and partners with companies including GSK, Alnylam Pharmaceuticals, and Brii Biosciences. Its AI-driven monoclonal antibody discovery engine identifies broadly neutralizing antibodies from recovered patients and vaccinated subjects. The company's model treats intellectual property as a portfolio of tradable assets that can be in-licensed, developed, and out-licensed based on clinical data. ### Is Vir Biotechnology structured as a biotech company or does it operate more like an investment fund? Vir is a publicly traded clinical-stage immunology company that functions with an asset-manager operating logic. It raises public-market equity, maintains a portfolio of drug programs spanning multiple therapeutic areas, and actively licenses, develops, and exits positions irrespective of internal discovery. Its board and largest investors include venture capital firms and sovereign wealth funds — ARCH Venture Partners, SoftBank, and Temasek held significant stakes at various points — reinforcing the capital-allocation identity. The company reports earnings and pipeline updates quarterly, disclosing clinical trial results and partnership economics as material events. ### What happened to Vir's COVID-19 antibody revenue and how is the business sustaining itself now? Sotrovimab generated over $2 billion in sales during 2021 under a partnership with GSK, but demand collapsed as SARS-CoV-2 variants emerged and the FDA revoked emergency use authorization in April 2022. Vir subsequently shifted focus away from COVID therapeutics and now funds operations from its balance sheet — which held approximately $1.6 billion in cash and investments as of year-end 2024 — while advancing programs in chronic hepatitis B, influenza, and solid tumor T-cell engagers. The company maintains no debt and has managed dilution conservatively relative to peers, positioning it for several years of clinical runway without requiring a partnership-driven revenue event. ### Which diseases does Vir Biotechnology currently target, and which has it explicitly deprioritized? Vir currently targets chronic hepatitis B (Phase 2 combination trial with an Alnylam-discovered asset), influenza A (Phase 1 for a prophylactic monoclonal antibody), and solid tumors via T-cell engagers. The company explicitly deprioritized COVID-19 antibody programs in 2022 and, as part of the April 2024 restructuring, narrowed its focus further away from earlier-stage HIV programs. HIV research remains a legacy area of institutional expertise — the firm holds foundational licensing agreements in broadly neutralizing HIV antibodies — but active clinical development has been suspended in favor of programs with nearer-term commercial potential. ## Related profiles - [Collective Mining](https://altss.com/profile/collective-mining-ltd) - [MBX Biosciences](https://altss.com/profile/mbx-biosciences-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/vir-biotechnology-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology